.
SLS financial statements
* Numbers in thousands
Year |
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
Capitalization * |
23 615 | 106 182 | 487 874 | 194 573 | 104 018 | 16 929 | 15 446 | 19 093 | 6 960 | 40 979 | 35 672 |
EV * |
12 682 | 73 375 | 449 979 | 179 325 | 79 027 | 15 243 | 24 115 | 13 756 | -317 | 7 327 | 7 327 |
Stock price $ |
19500 | 51000 | 162300 | 48900 | 20100 | 2550 | 330 | 73 | 2.72 | 6.1 | 5.31 |
Number of shares * |
1 | 2 | 3 | 4 | 5 | 7 | 47 | 262 | 2 559 | 6 718 | 6 718 |
EPS |
-9 483,90 | -16 795,90 | -25 508,30 | -9 199,80 | -12 348,20 | -3 547,07 | -507,49 | -105,80 | -7,54 | 0,00 | 0,00 |
Revenue * |
0 | 0 | 2 487 | 9 319 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
Net income * |
-11 485 | -34 969 | -76 678 | -36 606 | -63 902 | -23 549 | -23 754 | -27 670 | -19 292 | -17 | -17 |
Operating profit * |
-20 787 | -21 199 | -33 840 | -52 222 | -34 220 | -31 867 | -21 156 | -31 089 | -17 208 | -17 | -17 |
Total liabilities * |
20 856 | 27 230 | 82 090 | 43 429 | 68 631 | 37 154 | 31 456 | 11 670 | 10 516 | 18 088 | 18 088 |
Net debt * |
-10 866 | -32 750 | -37 895 | -15 248 | -24 991 | -1 686 | 8 669 | -5 337 | -7 060 | -33 652 | -33 652 |
Total assets * |
30 968 | 54 986 | 87 976 | 80 488 | 82 144 | 65 811 | 33 526 | 16 915 | 16 609 | 38 839 | 38 839 |
Equity * |
10 112 | 27 756 | 5 886 | 37 059 | 13 513 | 28 657 | 2 070 | 5 245 | 6 093 | 27 961 | 27 961 |
Cash and investments * |
11 433 | 35 485 | 47 787 | 23 650 | 29 730 | 18 083 | 2 319 | 5 337 | 7 277 | 35 302 | 35 302 |
Over the past 10 years, the maximum capitalization of SELLAS Life Sciences Group, Inc. is 487 874, the minimum is 6 960. Maximum net income 0, Minimum net income -76 678. The maximum price of SLS shares is 162300, the minimum price is 2.72.
.
SLS valuation
Year |
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-2,06 | -3,04 | -6,36 | -5,32 | -1,63 | -0,72 | -0,65 | -0,69 | -0,36 | -2 445,50 | -2 128,79 |
P/B |
2,34 | 3,83 | 82,89 | 5,25 | 7,70 | 0,59 | 7,46 | 3,64 | 1,14 | 1,47 | 1,28 |
P/S |
0,00 | 0,00 | 196,17 | 20,88 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 21 568,00 | 18 774,80 |
E/P |
-49% | -33% | -16% | -19% | -61% | -139% | -154% | -145% | -277% | 0% | 0% |
P/FCF |
-1,60 | -5,07 | -10,90 | -4,02 | -2,15 | -0,38 | -1,41 | -0,63 | -0,39 | -3,93 | -3,42 |
.
SLS profitability
Year |
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
ROE |
-114% | -126% | -1 303% | -99% | -473% | -82% | -1 148% | -528% | -317% | 0% | |
ROA |
-94% | -97% | -141% | -123% | -118% | -62% | -170% | -426% | -214% | 0% | |
ROIC |
-105% | -54% | -133% | -98% | -136% | -90% | -236% | -284% | -152% | 0% |